Reference data : LOINC code

Filter


Clear filter

Results
108,248 results found
Loinc Number Component Property System Time aspect ScaleType MethodType Relat_nms loincStatus Long Common name answerList chngType <span class='defaultText'>DefinitionDescription</span> dtLastCh exactCmspy exampleUnits exmplAnswers externalCopyrightNotice formula hl7FieldSubfieldId InpcPercentage ipccUnits loincClass loincFinal loincNum mapTo methodTyp molarMass naaccrId orderObs panelElements reference scope setRoot shortName source surveyQuestSrc surveyQuestText unitsRequired acssym relatedNames2 VersionLastChanged VersionFirstRelease ValidHL7AttachmentRequest PanelType AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
100041-3 Aminoglycoside Susc Isolate Pt OrdQn &nbsp; &nbsp; ACTIVE Aminoglycoside [Susceptibility] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 100041-3 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Aminoglycoside Susc Islt &nbsp; &nbsp; &nbsp; N &nbsp; Amikacin; Aminoglycosides; ANTIBIOTIC SUSCEPTIBILITIES; AST; c288; Gentamicin; Islt; Isol; Neomycin; Point in time; Random; Streptomycin; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Tobramycin 2.72 2.72 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100042-1 Atovaquone Susc Isolate Pt OrdQn &nbsp; &nbsp; ACTIVE Atovaquone [Susceptibility] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 100042-1 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Atovaquone Susc Islt &nbsp; &nbsp; &nbsp; N &nbsp; ANTIBIOTIC SUSCEPTIBILITIES; AST; Atavaquone; Islt; Isol; Mepron; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty 2.72 2.72 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100043-9 Azithromycin+Ethambutol Susc Isolate Pt OrdQn &nbsp; &nbsp; ACTIVE Azithromycin+Ethambutol [Susceptibility] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 100043-9 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Azithro+Ethambut Susc Islt &nbsp; &nbsp; &nbsp; N &nbsp; ANTIBIOTIC SUSCEPTIBILITIES; AST; Azithro+Ethambut; Etambol; Ethamb; Inagen; Islt; Isol; Myambutol; Mycobutol; Olbutam; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Zithromax 2.72 2.72 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100044-7 Cefcapene Susc Isolate Pt OrdQn &nbsp; &nbsp; ACTIVE Cefcapene [Susceptibility] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 100044-7 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Cefcapene Susc Islt &nbsp; &nbsp; &nbsp; N &nbsp; ANTIBIOTIC SUSCEPTIBILITIES; AST; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty 2.72 2.72 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100045-4 Cefozopran Susc Isolate Pt OrdQn &nbsp; &nbsp; ACTIVE Cefozopran [Susceptibility] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 100045-4 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Cefozopran Susc Islt &nbsp; &nbsp; &nbsp; N &nbsp; ANTIBIOTIC SUSCEPTIBILITIES; AST; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty 2.72 2.72 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100046-2 Cefquinome Susc Isolate Pt OrdQn &nbsp; &nbsp; ACTIVE Cefquinome [Susceptibility] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 100046-2 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 CEQ Susc Islt &nbsp; &nbsp; &nbsp; N &nbsp; ANTIBIOTIC SUSCEPTIBILITIES; AST; CEQ; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty 2.72 2.72 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100047-0 Cefteram Susc Isolate Pt OrdQn &nbsp; &nbsp; ACTIVE Cefteram [Susceptibility] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 100047-0 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Cefteram Susc Islt &nbsp; &nbsp; &nbsp; N &nbsp; ANTIBIOTIC SUSCEPTIBILITIES; AST; Cefterame; Cefteramum; Ceftetrame; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty 2.72 2.72 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100048-8 Clarithromycin+Ethambutol Susc Isolate Pt OrdQn &nbsp; &nbsp; ACTIVE Clarithromycin+Ethambutol [Susceptibility] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 100048-8 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Clarithro+Ethamb Susc Islt &nbsp; &nbsp; &nbsp; N &nbsp; ANTIBIOTIC SUSCEPTIBILITIES; AST; Biaxin; Claripen; Clarithro+Ethamb; Etambol; Ethamb; Inagen; Islt; Isol; Klacid; Myambutol; Mycobutol; Olbutam; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty 2.72 2.72 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100049-6 Eravacycline Susc Isolate Pt OrdQn &nbsp; &nbsp; ACTIVE Eravacycline [Susceptibility] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 100049-6 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Eravacycline Susc Islt &nbsp; &nbsp; &nbsp; N &nbsp; ANTIBIOTIC SUSCEPTIBILITIES; AST; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty 2.72 2.72 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
10005-7 R wave duration.lead V2 Time Heart Pt Qn EKG &nbsp; ACTIVE R wave duration in lead V2 &nbsp; MIN DefinitionDescription &nbsp; &nbsp; s &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; EKG.MEAS &nbsp; 10005-7 &nbsp; EKG &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 R wave dur L-V2 &nbsp; &nbsp; &nbsp; Y &nbsp; Cardiac; Cardio; Cardiology; Durat; ECG; EKG.MEASUREMENTS; Electrocardiogram; Electrocardiograph; Heart Disease; Hrt; Painter's colic; PB; Plumbism; Point in time; QNT; Quan; Quant; Quantitative; R prime; R' wave dur L-V2; R wave dur L-V2; Random; Right 2.48 1.0i &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; s &nbsp; &nbsp; &nbsp; 0
100050-4 Erythromycin+Ethambutol Susc Isolate Pt OrdQn &nbsp; &nbsp; ACTIVE Erythromycin+Ethambutol [Susceptibility] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 100050-4 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Erythro+Ethamb Susc Islt &nbsp; &nbsp; &nbsp; N &nbsp; ANTIBIOTIC SUSCEPTIBILITIES; AST; c212; EES; Erygel; Erythro+Ethamb; Erythromycn; Etambol; Ethamb; Ilosone; Ilotycin; Iltycin; Inagen; Islt; Isol; Myambutol; Mycobutol; Olbutam; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty 2.72 2.72 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100051-2 Ethambutol+rifAMPin Susc Isolate Pt OrdQn &nbsp; &nbsp; ACTIVE Ethambutol+rifAMPin [Susceptibility] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 100051-2 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Ethambutol+rifAMPin Susc Islt &nbsp; &nbsp; &nbsp; N &nbsp; ANTIBIOTIC SUSCEPTIBILITIES; AST; c301; Etambol; Ethamb; Inagen; Islt; Isol; Myambutol; Mycobutol; Olbutam; Point in time; Random; RIF; Rifadin; Rifampicin; Rimactane; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty 2.72 2.72 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100052-0 Flomoxef Susc Isolate Pt OrdQn &nbsp; &nbsp; ACTIVE Flomoxef [Susceptibility] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 100052-0 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Flomoxef Susc Islt &nbsp; &nbsp; &nbsp; N &nbsp; ANTIBIOTIC SUSCEPTIBILITIES; AST; Flomoxefum; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty 2.72 2.72 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100053-8 Fluoroquinolone Susc Isolate Pt OrdQn &nbsp; &nbsp; ACTIVE Fluoroquinolone [Susceptibility] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 100053-8 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 FLQ Susc Islt &nbsp; &nbsp; &nbsp; N &nbsp; ANTIBIOTIC SUSCEPTIBILITIES; AST; FLQ; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty 2.72 2.72 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100054-6 Gamithromycin Susc Isolate Pt OrdQn &nbsp; &nbsp; ACTIVE Gamithromycin [Susceptibility] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 100054-6 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Gamithromycin Susc Islt &nbsp; &nbsp; &nbsp; N &nbsp; ANTIBIOTIC SUSCEPTIBILITIES; AST; Bovine Respiratory Disease; BRD; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Vet; Veterinary; Zactran 2.72 2.72 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100055-3 Optochin Susc Isolate Pt OrdQn &nbsp; &nbsp; ACTIVE Optochin [Susceptibility] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 100055-3 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Optochin Susc Islt &nbsp; &nbsp; &nbsp; N &nbsp; ANTIBIOTIC SUSCEPTIBILITIES; AST; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty 2.72 2.72 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100056-1 Panipenem Susc Isolate Pt OrdQn &nbsp; &nbsp; ACTIVE Panipenem [Susceptibility] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 100056-1 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Panipenem Susc Islt &nbsp; &nbsp; &nbsp; N &nbsp; ANTIBIOTIC SUSCEPTIBILITIES; AST; Islt; Isol; Panipenum; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty 2.72 2.72 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100057-9 Prothionamide Susc Isolate Pt OrdQn &nbsp; &nbsp; ACTIVE Prothionamide [Susceptibility] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 100057-9 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Prothionamide Susc Islt &nbsp; &nbsp; &nbsp; N &nbsp; ANTIBIOTIC SUSCEPTIBILITIES; AST; Islt; Isol; Point in time; Protionamide; PTH; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty 2.72 2.72 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100058-7 Prulifloxacin Susc Isolate Pt OrdQn &nbsp; &nbsp; ACTIVE Prulifloxacin [Susceptibility] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 100058-7 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Prulifloxacin Susc Islt &nbsp; &nbsp; &nbsp; N &nbsp; ANTIBIOTIC SUSCEPTIBILITIES; AST; Islt; Isol; Point in time; Pruquin; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty 2.72 2.72 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100059-5 Rifapentine Susc Isolate Pt OrdQn &nbsp; &nbsp; ACTIVE Rifapentine [Susceptibility] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 100059-5 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Rifapentine Susc Islt &nbsp; &nbsp; &nbsp; N &nbsp; ANTIBIOTIC SUSCEPTIBILITIES; AST; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty 2.72 2.72 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
10006-5 R wave duration.lead V3 Time Heart Pt Qn EKG &nbsp; ACTIVE R wave duration in lead V3 &nbsp; MIN DefinitionDescription &nbsp; &nbsp; s &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; EKG.MEAS &nbsp; 10006-5 &nbsp; EKG &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 R wave dur L-V3 &nbsp; &nbsp; &nbsp; Y &nbsp; Cardiac; Cardio; Cardiology; Durat; ECG; EKG.MEASUREMENTS; Electrocardiogram; Electrocardiograph; Heart Disease; Hrt; Painter's colic; PB; Plumbism; Point in time; QNT; Quan; Quant; Quantitative; R prime; R' wave dur L-V3; R wave dur L-V3; Random; Right 2.48 1.0i &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; s &nbsp; &nbsp; &nbsp; 0
100060-3 Tildipirosin Susc Isolate Pt OrdQn &nbsp; &nbsp; ACTIVE Tildipirosin [Susceptibility] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 100060-3 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Tildipirosin Susc Islt &nbsp; &nbsp; &nbsp; N &nbsp; ANTIBIOTIC SUSCEPTIBILITIES; AST; Bovine Respiratory Disease; BRD; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Vet; Veterinary; Zuprevo 2.72 2.72 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100061-1 Tosufloxacin Susc Isolate Pt OrdQn &nbsp; &nbsp; ACTIVE Tosufloxacin [Susceptibility] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 100061-1 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Tosufloxacin Susc Islt &nbsp; &nbsp; &nbsp; N &nbsp; ANTIBIOTIC SUSCEPTIBILITIES; AST; Islt; Isol; Ozex; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty 2.72 2.72 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100062-9 Standard Dermatology Outcome Measures panel - ^Patient Pt - SDOM &nbsp; ACTIVE Standard Dermatology Outcome Measures panel &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; Copyright �© 2016 The Regents of the University of California and Emory University. Used with permission. &nbsp; &nbsp; &nbsp; &nbsp; PANEL.CLIN &nbsp; 100062-9 &nbsp; SDOM &nbsp; &nbsp; Order &nbsp; &nbsp; &nbsp; 0 SDOM panel &nbsp; &nbsp; &nbsp; N &nbsp; CLIN; Pan; PANEL.CLINICAL; Panl; Pnl; Point in time; Random; SDOM panel 2.72 2.72 &nbsp; Panel &nbsp; &nbsp; Copyright �© 2016 The Regents of the University of California and Emory University. Used with permission. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100063-7 Primary skin concern Find ^Patient Pt Nom &nbsp; &nbsp; ACTIVE Primary skin concern &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; CLIN &nbsp; 100063-7 &nbsp; &nbsp; &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 Primary skin concern &nbsp; &nbsp; &nbsp; N &nbsp; CLIN; Finding; Findings; Integument; Nominal; Point in time; Random 2.72 2.72 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
108,248 results found